Cambridge biotechnology company bluebird bio, said Monday that Wendy Dixon, Ph.D., and David Schenkein, M.D., have joined the company’s board of directors.
Bluebird bio is a clinical-stage biotechnology company that seeks to help patients with severe genetic and orphan diseases by using gene therapy.Dixon was chief marketing officer and president of global marketing at Bristol-Myers Squibb Company from December 2001 until May 2009 and served on the CEO’s executive committee.
Since 2009, Schenkein has been chief executive officer at Agios Pharmaceuticals. He has a proven track record in drug development and a deep oncology skill set, bluebird bio said in a press release.
Commenting on Dixon and Schenkein in a statement, bluebird bio chief executive Nick Leschly said, “Both have demonstrated clear leadership and expertise within their respective fields. Wendy has extensive experience in all aspects of drug commercialization, while David has a proven track record in innovative oncology drug development and hematologic transplantation. Their experiences will be invaluable to bluebird as we advance multiple gene therapy programs towards the market.”